An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product
NCT02143843
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
75
Enrollment
INDUSTRY
Sponsor class
Conditions
Primary Open-Angle Glaucoma
Ocular Hypertension
Interventions
DRUG:
Bimatoprost
Sponsor
ForSight Vision5, Inc.